Startup CytoScale Diagnostics to Commercialize UCLA's Single-Cell Protein Biomarker Platform
August 06, 2010
Startup CytoScale Diagnostics to Commercialize UCLA's Single-Cell Protein Biomarker Platform
The platform can detect proteins in samples as small as 1,000 cells, potentially offering an approach for biomarker discovery and diagnostic work using highly limited tissue sources, said one of its developers.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UCLA Study Identifies Leukemia Pathways Potentially Involved in Gleevec Resistance
March 25, 2011 / ProteoMonitor - Phosphoproteomic Profiling Suggests Src Inhibitors Useful as Kidney Cancer Treatment
June 3, 2011 / ProteoMonitor - ASU Biodesign Scientists Hope to Apply Direct-to-Consumer Model to Proteomics Testing
February 4, 2011 / ProteoMonitor - UCLA Team Builds Microfluidic Platform for Measuring Protein Kinase Activity
November 19, 2010 / ProteoMonitor - NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor